® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,
1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13
th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. The findings will be simultaneously published in
The Lancet.
“This is the first randomized trial specific to metastatic papillary renal cell carcinoma to show a clinically and statistically significant benefit with a targeted therapy, CABOMETYX, over an existing standard of care,” said Dr. Sumanta Pal, Clinical Professor and Co-Director of the Kidney Cancer Program, City of H
Global Antidepressant Drugs Market Size, Status and Forecast 2021-2028
amiFebruary 13, 2021 15
The life of human beings have become highly complex in recent times, and remarks such as life was less complicated years back are often heard. Change in lifestyle, especially in cities and towns, is being seen around the globe. Urbanization efforts by government bodies and higher income offered in urban locations can be cited as a major reason for the migration of people towards cities and towns. Job-related stress, especially in developing and developed countries, is a leading cause of depression. Furthermore, there is an increased chance of depression in individuals who have got a family history of depression, experienced childhood trauma, a less active frontal lobe in the brain and consumption of drugs, amongst others. In case of drug use, studies show that around 21% of individuals who have used banned substances (drugs) experience depression at some stage in their life, which in
TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) reported new, late-breaking phase 3 data from the TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620. The phase 3
Regenerative Medicine Market worth $17 9 billion by 2025 texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.